title: Nivolumab for advanced squamous cell lung cancer: what are the next steps?
authors.affiliation: Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal. Electronic address: ramello@ualg.pt.
authors.forename: Ramon Andrade
authors.initials: RA
authors.lastname: de Mello
authors.affiliation: Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal.
authors.forename: Inés
authors.initials: I
authors.lastname: Pousa
authors.affiliation: Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal.
authors.forename: Deolinda
authors.initials: D
authors.lastname: Pereira
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab